Biblio

Author Title [ Type

] Year

Filters: Author is Hazenberg, Mette D [Clear All Filters]

Journal Article

J Munneke M, Björklund AT, Mjösberg JM, Garming-Legert K, Bernink JH, Blom B, Huisman C, van Oers MHJ, Spits H, Malmberg K-J, et al. Activated innate lymphoid cells are associated with a reduced susceptibility to graft versus host disease. Blood. 2014.

van Lier YF, de Bree GJ, Jonkers RE, Roelofs JJTH, Berge IJMTen, Rutten CE, Nur E, Kuijpers TW, Hazenberg MD, Zeerleder SS. Allogeneic hematopoietic cell transplantation in the management of GATA2 deficiency and pulmonary alveolar proteinosis. Clin Immunol. 2020:108522.

Sijs-Szabo A, Dinmohamed AG, Versluis J, van der Holt B, Bellido M, Hazenberg MD, van Gelder M, Schaap NPM, Meijer E, van der Wagen LE, et al. Allogeneic Stem Cell Transplantation in Patients >40 Years of Age With Acute Lymphoblastic Leukemia: Reduced Intensity Versus Myeloablative Conditioning. Transplantation. 2023.

Aydin M, de Leeuw DC, Rutten CE, Visser OJ, Tang MWai, van Roessel C, Janssen JJW, Biemond BJ, van de Loosdrecht AA, Hazenberg MD, et al. ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non-myeloablative conditioning. Br J Haematol. 2023.

Atsuta Y, Baldomero H, Neumann D, Sureda A, DeVos JD, Iida M, Karduss A, Purtill D, Elhaddad AM, Bazuaye NG, et al. Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors. Haematologica. 2024.

Van der Meer JMR, Bulder I, Kuijk C, Kleijer M, Verheij MW, Omar SZ, Haverkate NJE, Dolstra H, Blom B, Hazenberg MD, et al. Generation of human ILC3 from allogeneic and autologous CD34 hematopoietic progenitors toward adoptive transfer. Cytotherapy. 2023.

Hazenberg MD, Haverkate NJE, van Lier YF, Spits H, Krabbendam L, Bemelman WA, Buskens CJ, Blom B, Shikhagaie MM. Human ectoenzyme-expressing ILC3: immunosuppressive innate cells that are depleted in graft-versus-host disease. Blood Adv. 2019;3(22):3650-3660.

Garrido HMGarcia, Haggenburg S, Schoordijk MCE, Meijer E, Tanck MWT, Hazenberg MD, Rutten CE, de Bree GJ, Nur E, Meek B, et al. Immunogenicity of a 5-dose pneumococcal vaccination schedule following allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2022.

Broers AEC, de Jong CN, Bakunina K, Hazenberg MD, Kooy Mvan Marwij, de Groot M, van Gelder M, Kuball J, van der Holt B, Meijer E, et al. Posttransplant Cyclophosphamide for Prevention of Graft-versus-Host Disease: The Prospective Randomized HOVON-96 Trial. Blood Adv. 2022.

J Munneke M, Spruit MJA, Cornelissen AS, van Hoeven V, Voermans C, Hazenberg MD. The Potential of Mesenchymal Stromal Cells as Treatment for Severe Steroid-Refractory Acute Graft-Versus-Host Disease: A Critical Review of the Literature. Transplantation. 2015.

Penack O, Marchetti M, Aljurf M, Arat M, Bonifazi F, Duarte RF, Giebel S, Greinix H, Hazenberg MD, Kröger N, et al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2024.

de Jong G, Janssen JJWM, Biemond BJ, Zeerleder SS, Ossenkoppele GJ, Visser O, Nur E, Meijer E, Hazenberg MD. Survival of early post-hematopoietic stem cell transplantation relapse of myeloid malignancies. Eur J Haematol. 2019.